₹
89.36
Jul 5
Business Description
Bafna Pharmaceuticals Ltd
ISIN : INE878I01022
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.3 | |||||
Debt-to-EBITDA | 1.67 | |||||
Interest Coverage | 2.67 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.47 | |||||
Beneish M-Score | -2.12 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 29 | |||||
3-Year EBITDA Growth Rate | 12.2 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 31.3 | |||||
3-Year Book Growth Rate | 12.5 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 87.22 | |||||
9-Day RSI | 76.73 | |||||
14-Day RSI | 66.23 | |||||
6-1 Month Momentum % | -12.05 | |||||
12-1 Month Momentum % | -20.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.2 | |||||
Cash Ratio | 0.04 | |||||
Days Inventory | 92.44 | |||||
Days Sales Outstanding | 100.84 | |||||
Days Payable | 107.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.46 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 29.88 | |||||
Operating Margin % | 4.01 | |||||
Net Margin % | 4.82 | |||||
FCF Margin % | -4.17 | |||||
ROE % | 9.31 | |||||
ROA % | 5.35 | |||||
ROIC % | 6.14 | |||||
ROC (Joel Greenblatt) % | 10.31 | |||||
ROCE % | 10.82 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.73 | |||||
PE Ratio without NRI | 28.73 | |||||
Price-to-Owner-Earnings | 70.92 | |||||
PS Ratio | 1.39 | |||||
PB Ratio | 2.62 | |||||
Price-to-Tangible-Book | 2.67 | |||||
Price-to-Operating-Cash-Flow | 22.26 | |||||
EV-to-EBIT | 24.25 | |||||
EV-to-EBITDA | 15.97 | |||||
EV-to-Revenue | 1.53 | |||||
EV-to-FCF | -36.72 | |||||
Price-to-Graham-Number | 1.85 | |||||
Price-to-Net-Current-Asset-Value | 7.65 | |||||
Earnings Yield (Greenblatt) % | 4.12 | |||||
FCF Yield % | -3.01 | |||||
Forward Rate of Return (Yacktman) % | -27.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Bafna Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 1,524.656 | ||
EPS (TTM) (₹) | 3.11 | ||
Beta | 0.31 | ||
Volatility % | 44.13 | ||
14-Day RSI | 66.23 | ||
14-Day ATR (₹) | 2.258355 | ||
20-Day SMA (₹) | 79.571 | ||
12-1 Month Momentum % | -20.58 | ||
52-Week Range (₹) | 73.35 - 116.45 | ||
Shares Outstanding (Mil) | 23.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bafna Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bafna Pharmaceuticals Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Bafna Pharmaceuticals Ltd Frequently Asked Questions
What is Bafna Pharmaceuticals Ltd(BOM:532989)'s stock price today?
When is next earnings date of Bafna Pharmaceuticals Ltd(BOM:532989)?
Does Bafna Pharmaceuticals Ltd(BOM:532989) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |